Begin main content

fluocinolone acetonide intravitreal implant

Last Updated: May 10, 2019
Result type: Reports
Project Number: SR0608-000
Product Line: Common Drug Review

Generic Name: fluocinolone acetonide intravitreal implant

Brand Name: Iluvien

Manufacturer: Knight Therapeutics Inc.

Indications: diabetic macular edema

Manufacturer Requested Reimbursement Criteria1: Indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

Submission Type: New

Project Status: Active

Biosimilar: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input posted March 06, 2019
Patient group input closed April 25, 2019
Clarification:

- Patient input submission received from the Canadian Association for Retired Persons (CARP), Canadian Council of the Blind (CCB), Diabetes Canada (DC) and the International Federation on Ageing (IFA)

Patient input summary sent for review to patient input groups May 06, 2019
Patient group comments on input summary closed May 13, 2019
Clarification:

- Patient input summary feedback received

Submission received April 03, 2019
Submission accepted for review April 17, 2019
Review initiated April 18, 2019
Draft CADTH review report(s) sent to applicant July 04, 2019
Comments from applicant on draft CADTH review report(s) received July 15, 2019
Redaction requests from applicant on draft CADTH review report(s) received July 22, 2019
CADTH review team's comments on draft CADTH review report(s) sent to applicant August 09, 2019
Canadian Drug Expert Committee (CDEC) meeting August 21, 2019
CDEC recommendation & redacted CADTH review report(s) sent to applicant and drug plans September 03, 2019
To
September 05, 2019